HC Wainwright initiated coverage on shares of ArriVent BioPharma (NASDAQ:AVBP - Free Report) in a report issued on Tuesday, Marketbeat.com reports. The brokerage issued a buy rating and a $25.00 price target on the stock.
A number of other research analysts also recently commented on the stock. Jefferies Financial Group initiated coverage on shares of ArriVent BioPharma in a research report on Tuesday, February 20th. They set a buy rating and a $35.00 target price on the stock. The Goldman Sachs Group began coverage on shares of ArriVent BioPharma in a research report on Tuesday, February 20th. They set a buy rating and a $27.00 target price on the stock. Finally, Citigroup began coverage on shares of ArriVent BioPharma in a research report on Tuesday, February 20th. They issued a buy rating and a $30.00 price objective on the stock.
Get Our Latest Report on AVBP
ArriVent BioPharma Stock Performance
NASDAQ AVBP traded up $0.18 during trading on Tuesday, reaching $16.52. 108,462 shares of the company's stock traded hands, compared to its average volume of 194,719. The company has a 50 day simple moving average of $18.27. ArriVent BioPharma has a 12-month low of $14.35 and a 12-month high of $25.95.
ArriVent BioPharma Company Profile
(
Get Free Report)
ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors.
Featured Articles
Before you consider ArriVent BioPharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ArriVent BioPharma wasn't on the list.
While ArriVent BioPharma currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
